1887
Preview this article:
Zoom in
Zoomout

What should be done about hepatitis-B-infected health-care workers?, Page 1 of 1

| /docserver/preview/fulltext/jmm/52/5/JMM5205.371-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05165-0
2003-05-01
2019-11-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/52/5/JM520501.html?itemId=/content/journal/jmm/10.1099/jmm.0.05165-0&mimeType=html&fmt=ahah

References

  1. Carman, W. F., Jacyna, M. R., Hadziyannis, S., Karayiannis, P., McGarvey, M. J., Makris, A. & Thomas, H. C. ( 1989;). Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet ii , 588–591.
    [Google Scholar]
  2. Department of Health ( 1993;). Protecting health care workers and patients from hepatitis B. Health Service Guidelines HSG (93) 40. London: Department of Health.
  3. Department of Health ( 1998;). Guidance for clinical health care workers: protection against infection with blood-borne viruses. Health Service Circular HSC (1998)/063. London: Department of Health.
  4. Department of Health ( 2000;). Hepatitis B infected health care workers. Health Service Circular HSC (2000)/02. London: Department of Health.
  5. Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J. & 10 other authors ( 2003;). Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med Med 348, 800–807.[CrossRef]
    [Google Scholar]
  6. Heptonstall, J., Barnes, J., Burton, E. & 25 other authors ( 1997;). Transmission of hepatitis B from four infected surgeons without hepatitis B e antigen.The Incident Investigation Teams and others. N Engl J Med 336, 178–184.[CrossRef]
    [Google Scholar]
  7. Lai, C. L., Chien, R. N. & Leung, N. W. & 9 other authors ( 1998;). A one-year trial of lamivudine for chronic hepatitis B.Asia Hepatitis Lamivudine Study Group. N Engl J Med 339, 61–68.[CrossRef]
    [Google Scholar]
  8. Liaw, Y.-F. ( 2002;). Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat 9, 393–399.[CrossRef]
    [Google Scholar]
  9. Liaw, Y.-F., Leung, N. W. Y., Chang, T. T. & 8 other authors ( 2000;). Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.Asia Hepatitis Lamivudine Study Group. Gastroenterology 119, 172–180.[CrossRef]
    [Google Scholar]
  10. Lindh, M., Horal, P., Dhillon, A. P. & Norkrans, G. ( 2000;). Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 7, 258–267.[CrossRef]
    [Google Scholar]
  11. Martinot-Peignoux, M., Boyer, N., Colombat, M. & 7 other authors ( 2002;). Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 36, 543–546.[CrossRef]
    [Google Scholar]
  12. Melegari, M., Scaglioni, P. P. & Wands, J. R. ( 1998;). Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27, 628–633.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.05165-0
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error